Volume 7.47 | Dec 3

Cord Blood News 7.47 December 3, 2015
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   CBN on Twitter
Short-Lived Human Umbilical Cord-Blood-Derived Neural Stem Cells Influence the Endogenous Secretome and Increase the Number of Endogenous Neural Progenitors in a Rat Model of Lacunar Stroke
In a rat model of lacunar stroke, scientists investigated the molecular mechanisms underlying the positive therapeutic effects of short-lived human umbilical cord-blood-derived neural stem cells through the distinct measurement of exogenous human and endogenous rat trophic factors. [Mol Neurobiol] Abstract | Full Article
Learn more about our standardized tools for cord blood banking
PUBLICATIONS (Ranked by impact factor of the journal)
Polymorphism in TGFB1 Is Associated with Worse Non-Relapse Mortality and Overall Survival after Stem Cell Transplantation with Unrelated Donors
The authors sequenced TGFB1 regulatory region and assigned allelic genotypes in a large cohort of hematopoietic stem cell transplantation patients and donors. They analyzed 522 unrelated donor-patient pairs and examined the combined effect of all the common polymorphisms in this genomic region. [Haematologica] Abstract | Full Article

Time-Dependent Effects of Clinical Predictors in Unrelated Hematopoietic Stem Cell Transplantation
Scientists present a systematic analysis and description of selected clinical predictors influencing the outcome of hematopoietic stem cell transplantation in a time-dependent manner based on a registry data analysis from the German Registry for Stem Cell Transplantation. [Haematologica] Abstract | Full Article

Long-Term Outcomes of Fludarabine, Melphalan and Antithymocyte Globulin as Reduced-Intensity Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency Disorders: A Prospective Single Center Study
Forty-five children affected by primary immunodeficiency disorders with a median age of 21 months underwent allogeneic hematopoietic stem cell transplantation in the researchers’ institute from 2007 to 2013. All patients received an identical reduced-intensity conditioning regimen. [Bone Marrow Transplant] Abstract

Effect of Immune Modulation in Relapsed Peripheral T-Cell Lymphomas after Post-Allogeneic Stem Cell Transplantation: A Study by the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)
Peripheral T-cell lymphoma carries a poor prognosis. To document a possible graft-versus-lymphoma effect in this setting, investigators evaluated the impact of immunomodulation in 63 patients with peripheral T-cell lymphoma who relapsed after allogeneic transplant in 27 SFGM-TC centers. [Bone Marrow Transplant] Abstract

Comparison of Biological Characteristics of Mesenchymal Stem Cells Derived from Maternal-Origin Placenta and Wharton’s Jelly
Investigators compared mesenchymal stem cells derived from Wharton’s jelly in the umbilical cord with those derived from the decidual basalis in the maternal part of the placenta to better understand the similarities and differences between these two cell types. [Stem Cell Res Ther] Full Article

Interaction of Natural Killer Cells with Neutrophils Exerts a Significant Antitumor Immunity in Hematopoietic Stem Cell Transplantation Recipients
Researchers examined whether natural killer cells exert an antitumor effect after syngeneic hematopoietic stem cell transplantation in a murine colon cancer model. [Cancer Med] Full Article

BDNF-Hypersecreting Human Umbilical Cord Blood Mesenchymal Stem Cells Promote Erectile Function in a Rat Model of Cavernous Nerve Electrocautery Injury
Investigators hypothesized that intracavernous injection of BDNF-hypersecreting human umbilical cord blood mesenchymal stem cells can ameliorate erectile dysfunction in a rat model of cavernous nerve electrocautery injury. [Int Urol Nephrol] Abstract

UM171 & UM729 - Get the Authentic Small Molecules for Ex Vivo Expansion of Human HSCs
Autologous Stem Cell Transplantation for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Efficacy in the Rituximab Era and Comparison to First Allogeneic Transplants. A Report from the EBMT Lymphoma Working Party
The authors reviewed the outcome of standard salvage therapy with an autologous stem cell transplant (SCT) over the last two decades and the outcome of allogeneic SCT in the most recent decade. [Bone Marrow Transplant] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.
Kite Pharma Initiates the ZUMA-3 Study to Support Registration of KTE-C19 for Relapsed or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) in Adult Subjects
Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous cell therapy products for the treatment of cancer, announced that it has initiated a Phase I/II clinical study of KTE-C19 (ZUMA-3) for the treatment of adult patients with r/r ALL. [Kite Pharma, Inc.] Press Release

Nohla Therapeutics Launches with Major US Cancer Research Institute Deal, Substantial Investment Round, and Key Appointments
Nohla Therapeutics Inc. announced the signing of an agreement with the Fred Hutchinson Cancer Research Center. The transaction with the Fred Hutch provides Nohla with a 20 year worldwide exclusive licensing agreement to seven patent families and know-how relating to an ex vivo expanded umbilical cord blood platform. [Nohla Therapeutics Inc.] Press Release

From our sponsor:
Discover how to reduce variability in primary neuron cultures with NeuroCult™ SM.
Watch the webinar.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW International Society for Cellular Therapy (ISCT) 2016
May 25-28, 2016
Singapore, Singapore

Visit our events page to see a complete list of events in the cord blood community.
NEW Postdoctoral Research Scientist – Lymphocyte Trafficking Mechanisms in Allogeneic Stem-Cell Transplantation (Columbia University Medical Center)

NEW Associate/Full Professor – Stem Cell Biology and Regeneration Medicine (Guangzhou Women and Children’s Medical Center)

Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

Assistant Member – Cord Blood Transplantation (Fred Hutchinson Cancer Research Center)

Faculty Positions – Regenerative Medicine for Organ Regeneration or Transplantation (The University of Texas Medical School at Houston)

Postdoctoral Fellow – Leukemia Research (City of Hope)

Faculty Member – Hematopoietic Cell Transplant (Fred Hutchinson Cancer Research Center)

Assistant or Associate Professor – Cell and Regenerative Biology (University of Wisconsin, Madison)

Assistant Member – Cord Blood Transplantation (Fred Hutchinson Cancer Research Center)

Research Associate – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us